کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2973892 1578462 2015 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Management of dyslipidaemia in statin-intolerant patients in light of AHA and NPA guidelines of 2013–2014
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
Management of dyslipidaemia in statin-intolerant patients in light of AHA and NPA guidelines of 2013–2014
چکیده انگلیسی

Statin-induced musculoskeletal effects account for about two-thirds of all adverse events and are the most common cause for the drug discontinuation. In view of its proven benefit for cardiovascular risk reduction, statins are the most important medications that should not be stopped until absolutely contraindicated. This concept is also endorsed by the recent AHA and NLA recommendations. Various strategies like lowering the daily dose, non-daily dosing, switching therapy, non-statin lipid-lowering drugs, Co-enzyme Q and dietary interventions have been tried with inconsistent results. Newly introduced molecules such as Mipomersen, Evolocumab and Alirocumab may show some promise in management of the statin-intolerant patients in future.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Indian College of Cardiology - Volume 5, Issue 2, June 2015, Pages 119–122
نویسندگان
, ,